Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2813 results

Press release / Apr 17, 2024

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis…
Novartis SEC filings
Pulse Update / Apr 09, 2024

Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
IgA nephropathy
Pulse Update / Apr 04, 2024

Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
Press release / Mar 22, 2024

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If…
Donations
Media Library / Mar 01, 2024

Novartis radioligand therapy (RLT) manufacturing facility
Media Library / Mar 01, 2024

Radioligand therapy (RLT) production line
Media Library / Mar 01, 2024

Refrigeration room at a Novartis radioligand therapy (RLT) manufacturing facility